Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login to start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

58 results

Radiation Oncology;  Endocrine Therapy;  Prostate Cancer

LuPSMA Plus Enzalutamide Extends High-Risk Metastatic CRPC Survival

From ESMO Congress 2023:
Combining prostate-specific membrane antigen-targeted radiotherapy and enzalutamide improves progression-free survival versus enzalutamide alone for high-risk metastatic castration-resistant prostate cancer 

Targeted Therapy;  Molecular Oncology;  Urothelial Cancer

THOR-2 Shows Erdafitinib RFS Gain For Progressive FGFR-Mutated NMIBC

From ESMO Congress 2023:
Patients with progressive non-muscle-invasive bladder cancer and select FGFR mutations have better recurrence-free survival with oral erdafitinib than an investigator’s choice of intravesical chemotherapy

Targeted Therapy;  Immunotherapy;  Clinical Research;  Colon and Rectal Cancer

Lenvatinib Plus Pembrolizumab Fails To Boost OS For Certain Metastatic CRC Patients

From ESMO World Congress on Gastrointestinal Cancer 2023:
The LEAP-017 trial did not show an overall survival advantage with lenvatinib plus pembrolizumab versus chemotherapy for microsatellite-stable, mismatch repair-proficient metastatic colorectal cancer

Cytotoxic Therapy;  Targeted Therapy;  Gastric Cancer;  Gastro-Oesophageal Junction Cancer

FLOT Plus Trastuzumab Boosts MPR Rate For Operable HER2-Positive Gastric Cancer

From ESMO World Congress on Gastrointestinal Cancer 2023:
Patients undergoing resection of HER2-positive gastric or oesophagogastric junction cancer may benefit from use of trastuzumab alongside perioperative chemotherapy

Translational Research;  Immunotherapy;  Gastro-Oesophageal Junction Cancer;  Oesophageal Cancer

Biomarker Analyses Identify CheckMate 577 Subgroups Who Gain Most Nivolumab Benefit

From ESMO World Congress on Gastrointestinal Cancer 2023:
Exploratory biomarker analyses show which patients with oesophageal or gastro-oesophageal junction cancer are most likely to receive clinical benefit from adjuvant nivolumab 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.